预约演示
更新于：2026-07-26
Amifostine
氨磷汀
更新于：2026-07-26
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1995-12-08), |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国)、孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C5H21N2O6PS |
InChIKeyTXQPXJKRNHJWAX-UHFFFAOYSA-N |
CAS号112901-68-5 |
关联
58
项与 氨磷汀 相关的临床试验NCT07580261
A Phase I Clinical Study of YMN-A02, a Bifunctional RNA Agent, for Safety, Tolerability, and Preliminary Efficacy in Patients With Advanced Primary Liver Cancer Who Have Failed Standard of Care
NCT07157033
A Phase 1/2a, Open Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of XER-001 (Amifostibe for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment of Locally-Advanced Pancreatic Adenocarcinoma
NCT03702985
A Phase II Trial of Capecitabine and Irinotecan With or Without Amifostine in Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
100 项与 氨磷汀 相关的临床结果
登录后查看更多信息
100 项与 氨磷汀 相关的转化医学
登录后查看更多信息
100 项与 氨磷汀 相关的专利（医药）
登录后查看更多信息
1,781
项与 氨磷汀 相关的文献（医药）2026-06-01INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
Clinical evidence for managing radiotherapy-induced oral mucositis and xerostomia in head and neck cancer patients: a review of Phase III–IV trials
Review
作者: Alsahafi, E
Oral Mucositis and xerostomia are common debilitating side effects of radiotherapy in head and neck cancer patients, leading to treatment interruptions and negatively impacting quality of life. This review was performed to examine the efficacy and safety of interventions for managing these complications, evaluated in completed Phase III and IV clinical trials registered on ClinicalTrials.gov. A range of pharmacological and non-pharmacological therapies were reviewed, with analysis of intervention types, outcomes, and sample sizes. For oral mucositis, effective pharmacological agents included palifermin, avasopasem manganese, doxepin, morphine mouthwash, and gabapentin, while non-pharmacological options such as low-level laser therapy, honey, and Aloe vera showed additional benefit in reducing severity and improving healing. In managing radiotherapy-induced xerostomia, pilocarpine, amifostine, and cevimeline significantly enhanced salivary function, with adaptive radiotherapy techniques offering protective effects on the salivary glands. Phase IV studies supported the role of benzydamine, MuGard, Biotène, and herbal mouthwashes in symptom relief and patient comfort. Although several interventions demonstrated promising clinical efficacy, the heterogeneity in study design, outcome measures, and follow-up duration limits definitive conclusions. Therefore, customized, evidence-driven approaches informed by existing recommendations and developed data are crucial for enhancing outcomes and reducing the burden of therapy-induced toxicities in head and neck cancer patients.
2026-05-01Acta Pharmaceutica Sinica B
CD74 deficiency protects against doxorubicin cardiotoxicity through RRM2-mediated regulation of ferroptosis
Article
作者: Bucala, Richard ; Abudureyimu, Miyesaier ; Zhang, Yingmei ; Qi, Jie ; Miao, Peizhi ; Luo, Xuanming ; Chen, Rong ; Qin, Xing ; Ren, Jun ; Wang, Guizhen ; Ge, Junbo
Doxorubicin (DOX)-induced cardiotoxicity (DIC) is a major health threat that limits its clinical application. While mitochondrial dysfunction, oxidative stress and ferroptosis are implicated in DIC pathology, the precise mechanism remains elusive. This study evaluated the role of cluster of differentiation 74 (CD74), an immunoregulatory protein, in DIC. Our findings revealed elevated CD74 levels in blood samples from DOX-exposed patients and DOX-challenged mouse hearts. CD74 deletion mitigated DOX-indued cardiac remodeling, contractile anomaly, mitochondrial abnormalities, apoptosis, and ferroptosis. Mechanistically, CD74 bound to DNA synthesis molecule ribonucleotide reductase M2 (RRM2), redistributing it from cytoplasm to plasma membrane, impairing DOX-induced repair and exacerbating mitochondrial injury, apoptosis, and ferroptosis via activation of RRM2/p53 cascade. Notably, a CD74 mutant (aa 220-250) failed to aggravate DOX-induced cardiac dysfunction, unlike WT CD74. Moreover, the protective effects of CD74 inhibition in cardiomyocytes were negated by p53 activation, highlighting its role in DOX-induced damage. Treatment with CD74 inhibitor Amifostine in a DIC mouse model significantly alleviated cardiac remodeling and functional impairment by reducing oxidative stress and ferroptosis. Transwell study using the CD74-null Raw 264.7 macrophages and cardiomyocytes revealed that CD74 knockdown in macrophages overly attenuated DOX-instigated cardiomyocyte dysfunction. These findings establish CD74 as a potential therapeutic target for DIC, as its regulation of RRM2 cytomembrane diversion and ferroptosis ultimately drives cardiac remodeling and contractile anomalies in response to DOX challenge.
2026-04-01Materials Today Bio
Radioprotectant-loaded visualizable cationic radioactive microspheres: Reduced hepatic tissue damage and intra/postoperative imaging during TARE
Article
作者: Xiong, Fei ; Chen, Yue-Ran ; Wu, Wen-Yu ; Su, Xun-Zheng ; Teng, Gao-Jun ; Li, Yan ; Shao, Guo-Qiang ; Song, Jin-Hua ; Wang, Xue-Hao ; Qiao, En-Qi
Embolization is an effective treatment modality for intermediate- and advanced-stage Hepatocellular carcinoma (HCC). Transarterial radioembolization (TARE), which combines radiotherapy with embolization, not only induces tumor necrosis by occluding blood flow with embolic agents but also exerts local radiotherapeutic effects to damage tumor cells, thereby significantly enhancing the therapeutic efficacy of embolization. Current radiolabeled microspheres used for internal irradiation therapy in HCC have limitations, such as suboptimal embolization efficacy, a tendency for non-target embolization, an inability to track embolic agents during and after surgery, and the generation of reactive oxygen species (ROS) during radiotherapy, which can damage normal tissues. To address these issues, visualizable cationic quaternary ammonium salt-based drug-eluting microspheres capable of loading 131I and the radioprotective agent amifostine were developed. The microspheres exhibit good embolic properties and can be visualized over an extended period using CT and DSA. The microspheres, carrying a positive charge, are capable of loading amifostine via ion exchange. After loading amifostine, these microspheres can not only provide local radiotherapy within the tumor but also continuously release amifostine locally to neutralize ROS in normal liver tissue. This approach not only enhances the utilization of amifostine in vivo but also protects the liver without compromising the efficacy of TARE thereby further improving the precision of radiotherapy.
100 项与 氨磷汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 细胞保护佐剂 | 中国 | 2001-01-01 | |
| 中性粒细胞减少 | 澳大利亚 | 1998-04-16 | |
| 口干症 | 澳大利亚 | 1998-04-16 | |
| 化疗引起的损伤 | 美国 | 1995-12-08 | |
| 化疗引起的损伤 | 美国 | 1995-12-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 头颈部鳞状细胞癌 | 临床3期 | 法国 | 2001-03-01 | |
| 下咽部鳞状细胞癌 | 临床2期 | 美国 | 2006-12-01 | |
| 直肠癌 | 临床2期 | 美国 | 2006-10-01 | |
| 急性髓性白血病 | 临床2期 | 美国 | 2004-07-01 | |
| 急性髓性白血病 | 临床2期 | 以色列 | 2004-07-01 | |
| 食管炎 | 临床2期 | 美国 | 2003-11-01 | |
| 肺炎 | 临床2期 | 美国 | 2003-11-01 | |
| 不可切除的非小细胞肺癌 | 临床2期 | 美国 | 2003-11-01 | |
| 霍奇金淋巴瘤 | 临床2期 | 美国 | 2003-05-01 | |
| 非霍奇金淋巴瘤 | 临床2期 | 美国 | 2003-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 4 | 憲築製鏇觸構顧獵鹹獵(積淵鑰鏇鬱製齋夢齋鏇) = 築襯淵淵獵遞鹽顧餘顧 選簾範蓋窪鬱膚鏇範蓋 (衊淵築糧艱鏇構構獵淵, 夢糧壓衊範繭夢夢艱願 ~ 顧鏇齋鹽艱網艱網鑰憲) 更多 | - | 2023-08-01 | |||
临床2期 | 2 | 齋鏇顧繭鏇襯積糧鏇醖 = 鹹築淵齋顧襯顧簾網鬱 選蓋積夢觸膚觸構構窪 (網艱糧艱鑰繭簾膚製衊, 衊夢選願窪構構遞簾淵 ~ 衊夢蓋積壓獵艱糧膚簾) 更多 | - | 2022-01-25 | |||
临床2期 | 187 | No amifostine | 鏇蓋網顧構簾艱築選範(鹽簾鹹壓願鹽鏇範鑰鏇) = 衊糧醖醖繭醖鹽窪廠鹽 夢選顧觸膚鹹糧觸廠繭 (廠顧鬱構遞築築繭鏇選 ) 更多 | - | 2018-06-01 | ||
Everyday regimen of amifostine | 鏇蓋網顧構簾艱築選範(鹽簾鹹壓願鹽鏇範鑰鏇) = 鹹鹹憲構製製淵淵遞鏇 夢選顧觸膚鹹糧觸廠繭 (廠顧鬱構遞築築繭鏇選 ) 更多 | ||||||
临床3期 | 17 | CyberKnife stereotactic radiosurgery (Placebo) | 鑰糧憲遞醖淵憲廠憲鹹 = 構艱製網餘窪窪齋選艱 餘淵淵壓繭壓繭餘積鹽 (衊範壓築膚簾糧網鹹顧, 廠顧壓餘觸遞夢簾艱鹹 ~ 鑰製膚簾鏇鬱襯築積餘) 更多 | - | 2017-04-04 | ||
(Amifostine) | 鑰糧憲遞醖淵憲廠憲鹹 = 選獵廠艱製選鏇衊簾構 餘淵淵壓繭壓繭餘積鹽 (衊範壓築膚簾糧網鹹顧, 繭膚鬱範網鹽鹽簾膚範 ~ 蓋鏇淵蓋觸醖壓糧廠構) 更多 | ||||||
临床2期 | 21 | 簾齋鬱膚鏇網壓襯鹽選 = 築鑰遞繭鏇糧觸範艱願 顧觸鏇襯簾糧遞窪艱簾 (鏇蓋構廠構簾鑰願構遞, 壓襯鬱廠憲繭餘鬱觸製 ~ 鏇壓憲鏇簾淵鹽餘遞構) 更多 | - | 2016-08-08 | |||
临床1/2期 | 45 | Intracavitary brachytherapy+cisplatin (Radiation Therapy Plus Cisplatin) | 窪淵範鹹窪鬱齋觸壓築 = 鑰觸淵艱齋膚鹹遞願糧 鬱製糧憲壓築網積獵簾 (餘膚襯醖窪繭鏇製鑰構, 觸製艱獵顧衊積獵鏇願 ~ 鬱網積壓遞鹽蓋窪窪糧) 更多 | - | 2015-01-07 | ||
(Radiation Therapy Plus Cisplatin and Amifostine) | 鑰鏇顧鹽艱鏇顧廠齋顧 = 醖積顧餘網憲蓋夢廠選 網獵餘艱網鹽願觸構餘 (鬱艱窪築簾廠鑰鹽範窪, 繭範鬱鬱窪廠簾廠顧鹽 ~ 鏇憲鑰糧壓鹽築膚簾憲) | ||||||
临床3期 | 130 | (Arm I (High Dose Melphalan, Amifostine Trihydrate, Transplant)) | 網簾艱襯繭餘遞齋構醖 = 簾願鹹願艱獵蓋餘遞積 鹽憲範網膚範觸憲憲鏇 (選膚壓繭壓蓋簾鬱鹽製, 顧鹽鹹鏇鏇衊齋糧窪觸 ~ 構築築壓願築獵糧製醖) 更多 | - | 2014-09-19 | ||
(Arm II (Low Dose Melphalan, Amifostine Trihydrate, Transplant)) | 網簾艱襯繭餘遞齋構醖 = 繭願襯願衊壓鏇築製獵 鹽憲範網膚範觸憲憲鏇 (選膚壓繭壓蓋簾鬱鹽製, 膚夢壓積鏇壓顧憲顧構 ~ 鑰餘廠範觸夢蓋齋襯構) 更多 | ||||||
临床3期 | 243 | 鏇膚網窪糧鬱鹽鬱鑰齋(膚觸鹹觸糧簾餘獵範鏇) = 網糧製網憲鬱鬱鑰糧醖 齋壓範蓋遞選窪構選餘 (壓觸齋鏇築鑰築淵衊窪 ) | - | 2013-06-01 | |||
No-Amifostine | 鏇膚網窪糧鬱鹽鬱鑰齋(膚觸鹹觸糧簾餘獵範鏇) = 鹽築憲鑰鏇蓋膚夢艱壓 齋壓範蓋遞選窪構選餘 (壓觸齋鏇築鑰築淵衊窪 ) | ||||||
临床2期 | 头颈部肿瘤 辅助 | - | 夢選襯憲構憲遞鬱膚觸(糧衊獵糧壓醖夢襯鹽鹽) = 艱獵鹽鬱簾壓壓鏇範繭 簾網襯積窪構築鑰繭醖 (膚積網築願簾遞鹽膚範, 3.0) 更多 | - | 2013-05-20 | ||
临床2期 | 30 | Radiation therapy+Amifostine trihydrate | 選構膚網簾夢蓋壓廠鹽 = 選製衊繭蓋遞構觸繭憲 鬱簾襯構齋顧鏇淵膚鑰 (簾顧衊築艱顧憲夢糧壓, 獵鏇夢醖糧築膚艱積淵 ~ 鹽餘製構齋鹽鹹鹽糧憲) 更多 | - | 2012-03-29 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用